Last updated: July 14, 2026
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc. (D.N.J., case no. 1:20-cv-01630) is a Hatch-Waxman patent litigation centered on AMARIN’s prescription fish oil product and Hikma’s generic entry strategy. The dispute is tied to asserted listed patents in the FDA Orange Book and culminates in a court record that affects launch timing, potential injunction scope, and freedom-to-operate for the challenged dosage form(s).
What patents were asserted in Amarin Pharma v. Hikma (1:20-cv-01630)?
The provided case identifier alone is insufficient to produce a complete and accurate litigation summary. A full patent-by-patent analysis requires the actual complaint, amended complaints, and the specific “asserted patents” list and claim constructions in the docket (e.g., the patents-in-suit, which claims were asserted, and whether Hikma contested validity/indefiniteness/obviousness-type categories).
What infringement theories did Amarin allege against Hikma in 1:20-cv-01630?
A credible infringement analysis requires the pleaded theory (direct infringement, inducement, contributory infringement), the accused product details (dosage strength, label/indications, packaging, and prescribing instructions), and the specific claim elements Amarin tied to Hikma’s proposed generic. Those items are not available from the case number alone.
Did Amarin plead inducement based on label or “intended use”?
Not determinable without the complaint or claim chart.
Were the claims tied to specific limitations (e.g., formulation/process/composition vs method-of-use)?
Not determinable without the asserted claims.
What defenses did Hikma raise (invalidity, unenforceability, non-infringement) in 1:20-cv-01630?
A defense-by-defense analysis requires the docket’s responsive filings (answer, Rule 12 motions if any, invalidity contentions, expert reports) and the specific invalidity grounds (anticipation, obviousness, written description, enablement, indefiniteness, and prosecution history estoppel). These details are not present in the supplied input.
Was there a Paragraph IV non-infringement/invalidity posture?
Paragraph IV framing is typical in these disputes, but whether this case is factually a Paragraph IV challenge (and if so, which patents and Orange Book listings were attacked) cannot be asserted without the FDA-linked notice(s) and the docket content.
When did Amarin v. Hikma resolve key motions, and how did that affect launch timing?
Launch-timing impact depends on court rulings on (i) preliminary injunction, (ii) claim construction, (iii) summary judgment, or (iv) trial outcomes, each of which must be pulled from the docket timeline. A summary judgment or injunction ruling can shift the generic entry window materially, but that information cannot be derived from the case number alone.
Was there an injunction or partial injunction in the case?
Not determinable without the final judgment order or any interim injunction/consent order on the docket.
Did the case end via settlement, dismissal, or final merits judgment?
Not determinable without the docket disposition entries.
What is the Orange Book status of the patents involved in 1:20-cv-01630?
Orange Book status analysis requires the drug name (and NDA/BLA), the listed patents, their expiration dates, and whether they are primary or secondary. The input does not include the NDA number or drug product name, so the Orange Book mapping cannot be produced accurately.
Which NDA strengths and dosage forms were implicated?
Not determinable without the asserted product/dose in the complaint.
Which listed patents were primary versus secondary?
Not determinable without Orange Book listings for the specific NDA.
What does this case mean for generic entry risk: what generic entry risks exist for Hikma?
Risk depends on whether the court upheld enforceable validity and infringement (blocking launch), found non-infringement (permitting launch), or entered a narrow or delayed remedy.
Does the record indicate a carve-out, design-around, or agreed launch date?
Not determinable without settlement terms or stipulations filed in the docket.
How does Amarin v. Hikma compare with other Amarin “fish oil” Hatch-Waxman disputes?
A defensible comparison requires (i) identification of the specific asserted patents and (ii) the outcomes in contemporaneous cases by other filers (often multiple ANDA/Hikma/comparators). The provided input does not supply the drug identity, asserted patent numbers, or outcome.
What litigation milestones and procedural dates matter most in 1:20-cv-01630?
A useful investor and licensing view typically lists:
- complaint filing date,
- TRO/preliminary injunction request and schedule,
- claim construction date(s),
- expert report deadlines,
- dispositive motion deadlines,
- trial date (if any),
- final judgment date,
- any appeal docketing date.
Those dates are not present in the provided information, so a timeline cannot be generated accurately.
Key Takeaways
- This is a patent infringement dispute tied to Amarin’s FDA-listed rights and Hikma’s generic entry. A full patent-by-patent and motion-by-motion litigation analysis requires the docket’s actual filings and the patents asserted, which are not supplied here.
- Launch and market exposure hinge on the specific outcome in the court’s merits or injunctive rulings. Those outcome details are not available from the case number alone.
FAQs
- What is the most common remedy pattern in Amarin-style Hatch-Waxman cases involving listed patents?
- How do claim construction rulings typically shift infringement outcomes in method-of-use versus composition claims?
- What settlement structures are common when a court does not enter a full injunction?
- How do secondary-listed patents affect generic “at-risk” launch timing when the primary patent falls?
- What documents in the docket are the fastest way to identify the patents-in-suit and the disputed claims?
References (APA)
- Not provided: no docket documents, court orders, or Orange Book listings were included in the input.
